Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis
- Design
- Meta-analysis · 164531 participants · Hard outcome
- Match to healthy normal-weight adults aged 55–75
- Different populationRCTs in diabetes and cardiovascular populations; dementia was an adverse-event or secondary outcome, not a designed endpoint.
- Could weight loss explain it?
- Possibly[Auto] Not addressed in abstract.
- Study tier
- Study tier 3Randomized data but with unplanned, sparsely ascertained outcomes; class-level result null.
- Assessment
- Version 2 · curated · Sep 13, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
Pooling 26 randomized trials, drugs for diabetes as a group did not reduce dementia, but the GLP-1 subgroup showed a 45% lower odds based on sparsely collected events. Weak randomized signal that the evoke trials later failed to support in established Alzheimer's disease.
01Findings
What the study reported
- Drugs
- Class unspecified
- Comparator
- controls
- Primary outcome
- Dementia or cognitive impairment reported in RCTs of cardioprotective glucose-lowering drugs
- Effect
- All classes OR 0.83 (NS); GLP-1RAs OR 0.55; SGLT2i OR 1.20
- 95% confidence interval
- 0.35 to 0.86 (GLP-1RA)
- Follow-up
- Not stated
- Adverse events
- Not extracted
- Limitations
- Auto-classified from abstract only; effect estimates, adverse events and limitations not extracted. Requires manual review.
Who was studied
- Mean age
- 64.4
- Sex distribution
- 34.9% female
- Diabetes status
- type 2 diabetes (most trials)
- Baseline condition
- Alzheimer's disease / MCI
- Sample size
- 531
Study quality details
- Study design
- Meta-analysis
- Sample size
- 531
- Randomization
- n/a
- Blinding
- not stated
- Comparator
- not stated
- Follow up duration
- not stated
- Outcome type
- mixed
- Replication
- 10 GLP-1RA trials pooled
- Consistency with other evidence
- not assessed (auto)
- Population applicability
- UNKNOWN
- Statistical precision
- CI reported: 95% CI, 0
- Risk of bias
- dementia not prespecified; ascertainment via adverse-event reporting; few events
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- Not stated in abstract
- Industry funded
- Unclear
- Manufacturer
- None identified
- Sponsor role
- not reported in abstract
- Author conflicts
- See published disclosures.
- Independent replication
- no RCT designed for this outcome
Funding is shown on every study and never used to score it.
03Claims
Claims this study bears on
- GLP-1 receptor agonist treatment reduces the risk of developing dementia.Supports
Meta-analysis of RCTs: GLP-1RAs OR 0.55 for dementia (secondary/adverse-event outcomes, few events); overall class result null.
04Source
The source, as retrieved
Abstract
[IMPORTANCE] Although diabetes is a risk factor for dementia, the effect of glucose-lowering therapy for prevention of incident dementia is uncertain. [OBJECTIVE] To determine whether cardioprotective glucose-lowering therapy (sodium-glucose cotransporter-2 inhibitors [SGLT2is], glucagon-like peptide-1 receptor agonists [GLP-1RAs], metformin, and pioglitazone), compared with controls, was associated with a reduction in risk of dementia or cognitive impairment, and among primary dementia subtypes. [DATA SOURCES] The PubMed and Embase databases were searched for studies published from inception of the database to July 11, 2024. [STUDY SELECTION] Randomized clinical trials comparing cardioprotective glucose-lowering therapy with controls that reported dementia or change in cognitive scores. Cardioprotective glucose-lowering therapies were defined as drug classes recommended by guidelines for reduction of cardiovascular events, based on evidence from phase III randomized clinical trials. Inclusion criteria were assessed independently and inconsistencies were resolved by consensus. [DATA EXTRACTION AND SYNTHESIS] Data were screened and extracted independently by 2 authors adhering to the PRISMA guidelines in August 2024. Random-effects meta-analysis models were used to estimate a pooled treatment effect. [MAIN OUTCOMES AND MEASURES] The primary outcome measure was dementia or cognitive impairment. The secondary outcomes were primary dementia subtypes, including vascular and Alzheimer dementia, and change in cognitive scores. [RESULTS] Twenty-six randomized clinical trials were eligible for inclusion (N = 164 531 participants), of which 23 trials (n = 160 191 participants) reported the incidence of dementia or cognitive impairment, including 12 trials evaluating SGLT2is, 10 trials evaluating GLP-1RAs, and 1 trial evaluating pioglitazone (no trials of metformin were identified). The mean (SD) age of trial participants was 64.4 (3.5) years and 57 470 (34.9%) were women. Overall, cardioprotective glucose-lowering therapy was not significantly associated with a reduction in cognitive impairment or dementia (odds ratio [OR], 0.83 [95% CI, 0.60-1.14]). Among drug classes, GLP-1RAs were associated with a statistically significant reduction in dementia (OR, 0.55 [95% CI, 0.35-0.86]), but not SGLT2is (OR, 1.20 [95% CI, 0.67-2.17]; P value for heterogeneity = .04). [CONCLUSIONS AND RELEVANCE] While cardioprotective glucose-lowering therapies were not associated with an overall reduction in all-cause dementia, this meta-analysis of randomized clinical trials found that glucose lowering with GLP-1RAs was associated with a statistically significant reduction in all-cause dementia.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Sep 13, 2026 | 40193122 first ingestion |